← Shionogi (SGIOY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Shionogi (SGIOY)
Healthcare · market cap $16.2B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Shionogi (SGIOY) is a Japanese pharmaceutical company with approximately 4,955 employees and a market cap of ~$14.8B. The company operates a broad pipeline spanning infectious disease, CNS, women's health, and metabolic disorders, with notable late-stage assets including S-217622 (COVID-19 antiviral), baloxavir marboxil (influenza), cefiderocol (resistant gram-negative infections), and multiple ospemifene formulations for atrophy/vaginal dryness. Near-term catalysts are concentrated in Phase 2 readouts for S-337395 (RSV), sivopixant (sleep apnea), and S-531011 (solid tumors) through mid-2027.
The catalyst path
- 2026-12-30 (est.)Phase 2 · S-337395imp 7/10
- 2026-12-31 (est.)Phase 2 · Sivopixantimp 7/10
- 2027-03-30 (est.)Phase 2 · S-488210/S-488211imp 7/10
- 2027-04-16 (est.)Phase 2 · S-531011imp 7/10
- 2027-08-08 (est.)Phase 2 · S-606001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ospemifene 60Mg Oral Tablet | Phase 3 | Atrophy |
| S-606001 | Phase 2 | Pompe Disease |
| S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis |
| Ospemifene (Dose 1) | Phase 3 | Atrophy |
| Ospemifene 30 mg | Phase 3 | Atrophy |
| Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy |
| Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) |
| S-309309 | Phase 2 | Obesity |
| Ospemifene 60 mg | Phase 3 | Atrophy |
| S-892216 | Phase 2 | COVID-19 |
| S-777469 400 mg | Phase 2 | Atopic Dermatitis |
| Cefiderocol | Phase 3 | Urinary Tract Infections |
| Ospemifene | Phase 3 | Vaginal Dryness |
| S-337395 | Phase 2 | Respiratory Syncytial Virus Infections |
| S-531011 | Phase 2 | Solid Tumors |
| Lusutrombopag | Phase 3 | Chronic Liver Disease |
| Standard of Care | Phase 2 | Gram-negative Bacterial Infections |
| S-217622 | Phase 3 | SARS-CoV-2 Infection |
| Baloxavir Marboxil | Phase 3 | Influenza |
| S-2367 1600 mg q.d. 54 Weeks | Phase 2 | Obesity |
Price & technical context
3-month
+3.2%
6-month
-21.8%
12-month
+1.9%
52-wk range
$7.93–$11.79
vs 50-day MA
-2.0%
vs 200-day MA
-7.4%
Realized vol
32.7%
Max drawdown
-29.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SGIOY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.